C. difficile toxin B Inhibitors
1 drugsAbout C. difficile toxin B
*Clostridioides difficile* toxin B is a key virulence factor produced by *C. difficile*, disrupting the intestinal lining and causing inflammation. It is a major contributor to antibiotic-associated diarrhea and colitis. Targeting toxin B is a therapeutic strategy to combat *C. difficile* infection (CDI).
There is currently no genetic evidence directly linking toxin B to specific diseases. However, its role in mediating the pathogenesis of CDI is well-established, supporting therapeutic intervention. Therapies neutralizing or inhibiting toxin B activity are crucial for improving patient outcomes.
One FDA-approved drug, ZINPLAVA (Merck), targets *C. difficile* toxin B for CDI treatment. ZINPLAVA is an antibody, representing the only approved modality. Further research into novel drug modalities targeting this toxin holds significant potential for advancing CDI treatment.
Top C. difficile toxin B Drugs
Merck is the only company with an approved drug targeting C. difficile toxin B.
The market is not competitive, suggesting high barriers to entry or limited interest.
C. difficile toxin B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets C. difficile toxin B, using antibody modality.
Exploring alternative modalities could provide a competitive advantage.
C. difficile toxin B Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on C. difficile toxin B. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 2 | 2 | 2 | 0 | 0 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 5 | 1 | 4 | 0 | 20% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
C. difficile toxin B Drug Approval Timeline (2016 - 2016)
The first and only drug, ZINPLAVA, was approved in 2016.
The approval timeline indicates a potentially unsaturated market with room for new entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on C. difficile toxin B. A trial counts if an approved drug acting on C. difficile toxin B is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.